

Product datasheet for TL319194V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

LINC00312 Human shRNA Lentiviral Particle (Locus ID 29931)

Product data:

Product Type: shRNA Lentiviral Particles

Locus ID: 29931

Synonyms: NAG7, ERR10, NAG-7, ERR-10

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: LOH3CR2A - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1

scramble control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM_013343, NR_024065, NM_013343.1, BC016278, BC009773, BM686558

Summary: This gene produces an intronless transcript that is thought to function as a tumor suppressor.

This transcript is downregulated in nasopharyngeal carcinoma and is a negative regulator of estrogen receptor signaling. A common polymorphism in this transcript allows the production of a 94 aa open reading frame in some individuals, which may interact directly with estrogen receptor 1 (PMID:15474036). This open reading frame does not exist on the reference genome haplotype, which is hypothesized to function through a non-coding RNA product. [provided by

RefSeq, Mar 2017

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact $\underline{\mathsf{techsupport}} \underline{\mathsf{morigene.com}}.$

If you need a special design or shRNA sequence, please utilize our custom shRNA service.



Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

> For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).